Kailera Therapeutics Raises $600 Million
Kailera Therapeutics, an obesity drug startup, has secured $600 million in funding from investors.
The financing round, one of the largest private biotech investments of the year, was led by Bain Capital's private equity group and included Royalty Pharma and sovereign wealth funds from Canada and Qatar.
Notably, several of Kailera's founding investors also contributed additional funds to the company.
The deal highlights the ongoing interest in weight loss drugs, despite past clinical disappointments.
- The Series B round was announced nearly a year after Kailera's launch with $400 million.
- The investment comes shortly after Pfizer announced plans to acquire Metsera, another private obesity drug developer, for $4.9 billion.
Author's summary: Kailera Therapeutics secures $600 million funding for obesity drug development.
More News
- EU Updates Age Verification Standards for Minors
- Borrower Monitoring, AI Processing, DPA, Verification Tools; Events and Training; Robots Will do What?
- “Man Utd are quite convinced…” - Fabrizio Romano reveals “complete” star will leave Old Trafford in 2026
- 'No Kings' protests against Trump planned nationwide, in what the GOP calls 'hate America' rallies
- B.C. Lions 37, Edmonton Elks 24: Robert Carter interception, TD run key in surging Vancouver win
- ‘No Kings’ protests liveblog: Scenes from around Southern Colorado’s big and small cities and towns
- Crowds gather across Colorado for ‘No Kings’ protests
- TBA, Appraisal, Reverse Mortgage Tools; STRATMOR on AI and Competition; Can the CFPB be Willed Away?